Marker Therapeutics (MRKR) vs Rocket One (RKTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed Rocket One (RKTO) over the past year, losing 7.5% versus a loss of 61.1%. Over five years, MRKR leads with a -93.9% price change compared with -97.8% for RKTO. Marker Therapeutics is the larger company by market cap ($16.2 million vs $16.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRKR | RKTO |
|---|---|---|
| Share price | $0.9716 | $0.6493 |
| Market cap | $16.20M | $16.17M |
| 1-day change | +2.27% | +0.50% |
| YTD return | -34.79% | -34.41% |
| 1-year return | -7.47% | -61.12% |
| 5-year return | -93.89% | -97.76% |
| EPS (TTM) | $-0.42 | $-0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.46 | $2.45 |
| 52-week low | $0.84 | $0.489 |
| Distance from 52-week high | -60.50% | -73.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +710.00% | — |
| Average volume | 65.70K | 554.01K |
| Shares outstanding | 16.67M | 24.90M |
| Employees | 5 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed RKTO by 53.7 percentage points over the past year.
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Rocket One
RKTO stock →Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
MRKR vs RKTO FAQ
Which is bigger, Marker Therapeutics or Rocket One?
Marker Therapeutics (MRKR) is larger, with a market capitalization of $16.20M compared with $16.17M for Rocket One (RKTO).
Which stock has performed better over the past year, MRKR or RKTO?
MRKR returned -7.47% over the past 12 months, compared with -61.12% for RKTO (price return, excluding dividends). Past performance does not predict future results.
Are Marker Therapeutics and Rocket One in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.